Notable Downgrades: OvaScience (OVAS), Sequenom Inc. (SQNM), BlackBerry (BBRY), Esperion Therapeutics (ESPR)

Analysts at JMP Securities downgraded OvaScience, Inc. (OVAS) from ‘Market Outperform’ to ‘Market Perform’ in a research report issued to clients on Tuesday.

Shares of the $242.67 million market cap company are down 7.22% year-over-year and 67.16% year-to-date.

Ovascience Inc., currently with a median Wall Street price target of $50 and a high target of $100, dropped $5.62 to $8.90 in recent trading.

Sequenom Inc. (SQNM) was downgraded from ‘Neutral’ to ‘Sell’ at Ladenburg Thalmann. The name was also downgraded to ‘Market Perform’ at William Blair.

Shares have traded today between $1.53 and $1.80 with the price of the stock fluctuating between $1.53 to $4.80 over the last 52 weeks.

Sequenom Inc. shares are currently changing hands at 11.01x this year’s forecasted earnings. Ticker has a t-12 price/sales ratio of 1.57. EPS for the same period registers at $0.15.

Shares of SQNM have lost $0.28 to $1.64 in mid-day trading on Tuesday, giving it a market cap of roughly $194 million. The stock traded as high as $4.80 in May 5, 2015.

BlackBerry Limited (BBRY) rating of ‘In-line’ was reiterated today at Imperial Capital with a price target decrease of $7 from $9.50 (versus a $6.30 previous close).

On valuation measures, BlackBerry Ltd. shares have a T-12 price/sales ratio of 1.27 and a price/book for the same period of 0.93. EPS is ($0.52). The name has a market cap of $3.27 billion and a median Wall Street price target of $7.00 with a high target of $11.00. Currently there are 2 analysts that rate BBRY a ‘Buy’, 16 rate it a ‘Hold’. 5 analysts rate it a ‘Sell’.

In terms of share statistics, BlackBerry Ltd. has a total of 523.98 million shares outstanding with 4.99% held by insiders and 56.60% held by institutions. The stock’s short interest currently stands at 17.60%, bringing the total number of shares sold short to 92.15 million.

BBRY currently prints a one year loss of about 39% and a year-to-date loss of around 43%.

Shares of Esperion Therapeutics, Inc. (ESPR) are down $14.36 to $20.73 in mid-day trading after Chardan Capital Markets reiterated its ‘Sell’ rating and lowered its 12-month base case estimate on the name by 7 points to $29 a share.

ESPR was down $15.03 at $20.06 in midday trade, moving within a 52-week range of $18.00 to $120.96. The name, valued at $451.12 million, opened at $26.00.

Be the first to comment

Leave a Reply

Your email address will not be published.


*